CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Concurrent Treatment for Substance Use Disorder and Trauma-Related Comorbidities: 2021 Update

Last updated: March 31, 2021
Project Number: RA1171-000
Product Line: Rapid Response
Research Type: Non-Pharma Mental Health Intervention
Report Type: Reference List
Result type: Report

Question

  1. What is clinical effectiveness of concurrent treatment for patients with substance use disorders and comorbid post-traumatic stress disorder, anxiety, or depression?
  2. What is the clinical effectiveness of the treatment of 1 condition for the improvement of all symptoms in patients with substance use disorder and comorbid post-traumatic stress disorder, anxiety, or depression?
  3. What are the evidence-based guidelines regarding the treatment of patients with substance use disorders and comorbid post-traumatic stress disorder, anxiety, or depression?

Key Message

Two systematic reviews and 8 randomized controlled trials were identified regarding the clinical effectiveness of concurrent treatment for patients with substance use disorders and comorbid post-traumatic stress disorder, anxiety, or depression. One systematic review and 2 non-randomized studies were identified regarding the clinical effectiveness of the treatment of 1 condition for the improvement of all symptoms in patients with substance use disorder and comorbid post-traumatic stress disorder, anxiety, or depression. Four evidence-based guidelines were identified regarding the treatment of patients with substance use disorders and comorbid post-traumatic stress disorder, anxiety, or depression.